<DOC>
	<DOCNO>NCT00549146</DOCNO>
	<brief_summary>Relatively little information available effect salmeterol/fluticasone combination fluticasone alone COPD patient partial reversible pulmonary obstruction . The purpose study compare effect salmeterol/fluticasone combination fluticasone alone deliver via Diskus/ACCUHALER inhaler subject COPD lung function 1 year period .</brief_summary>
	<brief_title>Treatment Of Partial Reversible Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description>Multi-centre , double-blind , randomise stratified parallel group study compare efficacy safety fluticasone propionate 500 mcg bd versus salmeterol/fluticasone combination 50/250 mcg bd via Diskus inhaler 1 year Chronic Obstructive Pulmonary Disease ( COPD ) patient partially reversible obstruction .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criterion : Established history chronic obstructive pulmonary disease ( COPD ) . Lung function parameter : FEV1/FVC ratio &lt; 70 % , FEV1 80 % 30 % predict , reversibility airway obstruction 12 % initial value minimum 200 mL . Signed date informed consent . Exclusion criterion : History asthma allergy . Unstable COPD 3 month study . Interference nonpulmonary medication disease COPD outcome parameter .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>reversibility</keyword>
	<keyword>COPD</keyword>
	<keyword>lung function</keyword>
</DOC>